MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis

Regulation of theMEToncogene: molecular mechanisms

(2016) Jack Zhang et al.   CARCINOGENESIS

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution

(2015) Nicholas McGranahan et al.   CANCER CELL

Update on Metastatic Gastric and Esophageal Cancers

(2015) Manish A. Shah   JOURNAL OF CLINICAL ONCOLOGY

Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification

(2015) Noëlle Weingertner et al.   PATHOLOGY

Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET)

(2014) Aaron M Gruver et al.   HISTOPATHOLOGY

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

(2014) Hansjochen Wilke et al.   LANCET ONCOLOGY

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2013) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Next-Generation Sequencing Reveals High Concordance of Recurrent Somatic Alterations Between Primary Tumor and Metastases From Patients With Non–Small-Cell Lung Cancer

(2013) Stéphane Vignot et al.   JOURNAL OF CLINICAL ONCOLOGY

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas

(2013) Sang Y Ha et al.   MODERN PATHOLOGY

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome

(2012) H E Lee et al.   BRITISH JOURNAL OF CANCER

Intratumor Heterogeneity: Evolution through Space and Time

(2012) C. Swanton   CANCER RESEARCH

Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer

(2012) Rafal Dziadziuszko et al.   Journal of Thoracic Oncology

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted therapies in the treatment of gastric cancer

(2011) Joanne NGEOW et al.   Asia-Pacific Journal of Clinical Oncology

MET Expression and Amplification in Patients with Localized Gastric Cancer

(2011) Y. Y. Janjigian et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Investigation of the recurrence patterns of gastric cancer following a curative resection

(2011) Jingyu Deng et al.   SURGERY TODAY

Intratumoural cytogenetic heterogeneity of sporadic colorectal carcinomas suggests several pathways to liver metastasis

(2010) José María Sayagués et al.   JOURNAL OF PATHOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases

(2008) S. H. Cheon et al.   ANNALS OF ONCOLOGY

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

(2008) C. Gravalos et al.   ANNALS OF ONCOLOGY